Finerenone Use in Coenzyme Q8B–Related Focal Segmental Glomerulosclerosis
Manaf Aljishi, Mohamed Khogali, Turki Alhussain, Tofol Alnashmi · 2026
Read Finerenone Use in Coenzyme Q8B–Related Focal Segmental Glomerulosclerosis by Manaf Aljishi, Mohamed Khogali, Turki Alhussain, Tofol Alnashmi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13676110.txt.
Description
Manaf Aljishi and co-authors present a 2026 case report on a new use for the drug finerenone in a rare genetic kidney disease. The disease scars the kidney's filters and often ignores standard immune-calming drugs. It stems from a fault in making coenzyme Q, a cell energy helper.
The patient was a 35-year-old woman with lasting protein in her urine after pregnancy and a strong family history of early kidney failure. Gene tests found the faulty gene, and standard drugs plus a supplement had failed or were not tolerated. After finerenone began in May 2024, her urine protein measure improved greatly. A single case cannot prove a treatment, but it flags an option for a disease with few choices left.
Catalog record
| CREATOR | Manaf Aljishi, Mohamed Khogali, Turki Alhussain, Tofol Alnashmi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |